icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

EU drugs regulator urges people to follow through on 2nd Covid vaccine doses as Delta variant continues to surge in Europe

EU drugs regulator urges people to follow through on 2nd Covid vaccine doses as Delta variant continues to surge in Europe
As the Delta variant becomes increasingly prevalent, the European Medicines Agency (EMA) has urged citizens to get their second Covid-19 vaccine shot. It is also reviewing reported side-effects of Johnson & Johnson’s jab.

In a press statement on Wednesday, the EMA said the growing prevalence of the Delta variant across the nations in the bloc had reinforced the importance of people getting their second Covid-19 dose to ensure maximum protection. 

“Preliminary evidence suggests that both doses of a two-dose Covid-19 vaccine like [Pfizer’s] Comirnaty, [Moderna’s] Spikevax or [AstraZeneca’s] Vaxzevria are needed to provide adequate protection against the Delta variant,” the statement reads, adding that the new strain may also be linked with increased hospitalization.

There are still 10 EU/EEA nations where 30% or more of the population over the age of 80 have not yet completed the recommended vaccination course, according to the EMA and European Centre for Disease Prevention and Control tracker. With the exception of the Johnson & Johnson vaccine, which has not been used as widely, all other vaccines are administered in a two-dose regimen. 

Also on rt.com J&J’s single-shot Covid-19 vaccine reviewed by EU’s medicines agency over rare nerve disorder after US reports one death

In other statements on Wednesday, the EMA provided updates on the safety and efficacy of the Covid-19 vaccines it has approved for use in the EU. Following on from Tuesday’s news that the agency would be investigating a US warning about cases of Guillain-Barré Syndrome associated with the Johnson & Johnson vaccine, the EMA said it had isolated 15 potentially linked cases in the EU. It said it could neither confirm nor rule out any causal relationship, however. 

On Monday, health authorities in the US warned of a possible link between the one-shot vaccine and the rare nerve disorder. Of 100 preliminary reports, 95 were serious cases that required hospitalization, and there was one reported death.  

The EMA also said it had concluded an investigation into nine cases of immune thrombocytopenia that were “possibly related” to the widely-used Moderna vaccine, but, again, there was no clear causal relationship. 

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.

Podcasts